Tratamiento de la hepatitis viral aguda c con interferón alfa 2b recombinante. Ensayo clínico

Revista Cubana de Medicina

Volumn 39, Issue 1, 2000, Pages 21-29

  Arús Soler, Enrique ^a   Rivera Reimón, Luis ^a,b   Infante Velázquez, Mirtha ^a,c   Pérez Lorenzo, Marlen ^a,c   Soto Argüelles, Grisel ^a,d   Gra Oramas, Bievenido ^a,e   Padrön Gonzälez, Guillermo ^a,f   Löpez Saura, Pedro ^a,f  

^a HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^b Hospital Militar Central Dr Carlos J Finlay   (Cuba)

^c INSTITUTO SUPERIOR DE MEDICINA MILITAR DR LUIS DÍAZ SOTO   (Cuba)

^d Centro Nacional Coordinador de Ensayos Clinicos   (Cuba)

^e INSTITUTO DE GASTROENTEROLOGÍA   (Cuba)

^f CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 32044474131     PISSN: 00347523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Arús E. Clínica y terapéutica de las hepatitis virales. En: Padrón GJ, ed. Bases moleculares para el estudio de las hepatitis virales. La Habana:Elfos Scientiae, 1998:43-78.
2. Hoofnagle JH, Carithers RL, Shapiro C, Asher N. Fulminant hepatic failure: Summary of workshop. Hepatology 1995;21:240.
3. Schimer M, Vogel W, Thaler J, Grunewald K, Umlauft F, Lewis WD, et al. Fulminant hepatic C virus infection. Lancet 1994;343:1433-4.
4. Gordon FD, Anastopoulos H, Khettry V, Loda M, Jerkins RL, Lewis WD, et al. Hepatitis C infection: a rare cause of fulminant hepatic failure. Am J Gastroenterol 1995;90:117-20.
5. Fonseca JCF, Ferreira LCL, Brazil LM, Castlho MC, Moss R, Barono M. Labrea Hepatitis. The role of hepatitis A (HAV), B(HBV), C (HCV) and D (HDV) infection (Preliminary report). Rev Inst Med Trop Sao Paulo 1992;34:609-12.
6. Ohnishi H, Sugihara J, Muto Y. Detection of anti-hepatitis C virus antibody in fulminant hepatic failure. Gastroenterol Jpn 1991;26(3Suppl):230-3.
7. Tandon BD, Irshad M, Acharya SK, Joshi YK. Hepatitis C virus infection is the major cause of severe liver disease in India. Gastroenterol Jpn 1992;26(3Suppl): 192-5.
8. Farci P, Alter HJ, Wong D. A long term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98.
9. Poynard T, Leriy V, Cohard M, Therenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778-89.
10. Padrón GJ, Lemos G, Sánchez G, Arús E, Domínguez R, Chinea G, et al. Evaluación de un sistema para la detección de anticuerpos contra un antígeno sintético del core del virus de Ika hepatitis C y su prevalencia en donantes de sangre. Biotecnol Aplicada 1994;11:165-70.
11. Arús AE, Hidalgo A, Acosta D. Estudio clínico y factores de riesgo en donantes de sangre portadores de anticuerpos contra el virus de la hepatitis C. 16 de abril 1998;195:24-9.
12. Padrón GJ, Rodríguez Z, Rivera L, Arús E, Beltrán J, Roca J, et al. El virus de la hepatitis C en donantes por plasmeféresis. Sangre 1995;40:187-90.
13. Arús E, García W, Rivera L, Padrón G, Gra B, Unpierre I, et al. Aspectos clínicos, bioquímicos e histológicos en donantes especiales por plasmaféresis con anti HVC positivo. Arch Gastroenterol Rep Dominicana 1999;7:8-11.
14. Alter MJ, Mast EE. The epidemiology of the viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-44.
15. Barrera JM, Bruguera M, Ercilla MG. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995;21:639-42.
16. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 1996;41:1248-55.
17. Ohnishi K, Nomura F, Lida S. Treatment of posttransfusion non-A, non-B acute hepatitis with human fibroblast beta interferon: a preliminary report. Am J Gastroenterol 1989;84:596-600.
18. Hagiwara H, Hayashi N, Kasahara A. Three cases of posttransfusion hepatitis C treated with interferon alfa. Dig Dis Sci 1992;37:632-4.
19. Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassioni D, et al. A multicenter randomized controlled trial of recombinant interferon alfa 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
20. Viladomiu L, Genesca J, Esteban JI, Allende H, González A, López-Talavera LC, et al. Interferon alfa in acute posttransfusion hepatitis C: a randomized controlled trial. Hepatology 1992;15:767-9.
21. Hwang SJ, Lee SD, Chan CY, Liu RH, Lo KJ. A randomized controlled trial of recombinant interferon alfa 2-b in the treatment of Chinese patients with acute posttransfusion hepatitis C. J Hepatol 1994;21:831-6.
22. Takano S, Satomura Y, Omata M. Japan Acute Hepatitis Coop Study Group. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Gastroenterology 1994;107:805-11.
23. Tassopoulos NC, Koutelou MG, Papatheodoridis G, Polychronaki H, Delladetsima I, Giannihakis T, et al. Recombinant human interferon alfa 2b treatment for acute non-A, non-B hepatitis. Gut 1993;34(Suppl):S130-S132.
24. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazehi F, et al. Reduction of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338:914-5.
25. Palmovic D, Kurelac I, Crnjakovic-Palmovic J. The treatment of acute posttransfusion hepatitis C with recombinant interferon alpha. Infection 1994;22:222-3.
26. Alberti A, Belussi F, Chemello L, Benregnu L, Pontisso P. Outcome of acute hepatitis C and role interferon alpha (IFN-2a) therapy. Proceeding of the International Symposium on Viral Hepatitis and Liver Disease. Tokyo, May 10-14, 1993(Abstract 27).
27. Marcellin P, Boyer M, Martinot S, Erlinger S. Interferon therapy in hepatitis C: benefits and limitations. En: Arroyo V, Bosh J, Bruguera M, Rodes J, eds. Therapy in liver disease. Barcelona: Masson, 1997:309-16.
28. Vogel W, Graziadei I, Umlauft F, et al. High-dose interferon alpha 2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996;41(Suppl 12):81S-85S.
29. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995;15:82-91.
30. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.